DEFA14A: Premier Acquired by Patient Square Capital for $2.6B

Premier, Inc. will be acquired by an affiliate of Patient Square Capital for $28.25 per share in cash, valuing the transaction at approximately $2.6 billion.

Summary

• Premier, Inc. has entered into a definitive agreement to be acquired by an affiliate of Patient Square Capital, a dedicated healthcare investment firm.
• Under the terms of the agreement, Patient Square Capital will acquire all shares of Premier for $28.25 per share in cash.
• The total transaction is valued at approximately $2.6 billion.
• Upon completion, Premier will transition to a private company, and its stock will no longer be listed or traded on NASDAQ or any other public exchange.
• The transaction is expected to close by the first quarter of calendar year 2026.
• Closing is contingent upon approval by Premier stockholders, satisfaction of regulatory approvals, and other customary closing conditions.

Sentiment

Score: 8

Explanation: The filing announces a definitive acquisition at a premium, offering immediate and certain value to shareholders, and outlines strategic benefits for the company under new ownership, despite the loss of public trading status.

Positives

• Stockholders will receive immediate and certain value of $28.25 per share in cash.
• Enhanced financial flexibility is expected to accelerate the advancement and tech-enablement of the product portfolio.
• The acquisition provides an opportunity to capitalize on emerging opportunities and continue innovation.
• Patient Square Capital brings deep industry expertise, significant capital, and a strong track record of helping companies reach their full potential.
• Patient Square has expressed a deep appreciation for Premier's employees and a commitment to investing in them.

Negatives

• Premier's stock will no longer be publicly traded on NASDAQ or any other exchange.
• The company will no longer have certain public company responsibilities, such as quarterly public financial reporting.
• Equity-based compensation programs will undergo adjustments due to the transition to a private company.

Risks

• Inability to consummate the proposed transaction within the anticipated time period, or at all, due to failure to obtain required regulatory approvals, stockholder approval, or complete contemplated financing arrangements.
• Adverse effects on the market price of Premier Class A Common Stock could occur due to announcements related to the proposed transaction.
• Disruption from the proposed transaction may make it more difficult to maintain business and operational relationships, including retaining and hiring key personnel and maintaining relationships with customers, vendors, and other business partners.
• The occurrence of any event, change, or other circumstances could give rise to the termination of the merger agreement.
• Risks related to disruption of current plans and operations or the diversion of management's attention from ongoing business operations due to the proposed transaction.
• Significant transaction costs are associated with the acquisition.
• Risk of litigation and/or regulatory actions related to the proposed transaction or unfavorable results from currently pending or future litigation and proceedings.

Future Outlook

Under Patient Square's ownership, Premier anticipates enhanced financial flexibility to accelerate the advancement and tech-enablement of its product portfolio, capitalize on emerging opportunities, and continue pushing the envelope of innovation. The company will no longer be subject to certain public company responsibilities, such as quarterly public financial reporting.

Management Comments

• "Premier entered into an agreement to be acquired by an affiliate of Patient Square Capital, a dedicated healthcare investment firm."
• "Under Patient Square's ownership, Premier will have enhanced financial flexibility to accelerate the advancement and tech-enablement of our product portfolio, capitalize on emerging opportunities and continue pushing the envelope of innovation."
• "Premier's Board carefully considered a wide range of strategic alternatives in recent years and unanimously determined that this transaction with Patient Square is in the best interests of Premier and its stockholders and, upon closing, will deliver immediate and certain value to our stockholders."
• "Until the transaction closes... it is business as usual at Premier."
• "We are confident that this transaction will benefit all of our stakeholders, including employees."
• "Patient Square has shown a deep appreciation for Premier's people and a commitment to investing in you all."
• "Overall, however, you should generally expect your total cash compensation and benefits to remain substantially comparable to what they are today."

Industry Context

The healthcare industry is undergoing rapid evolution, and this acquisition positions Premier for long-term growth by leveraging Patient Square's deep industry expertise and capital. This move aligns with broader industry trends of private equity firms investing in healthcare technology and services to drive innovation, improve operational efficiencies, and consolidate market positions.

Comparison to Industry Standards

• NA

Legal Proceedings

• Risk of litigation and/or regulatory actions related to the proposed transaction.
• Risk of unfavorable results from currently pending litigation and proceedings or litigation and proceedings that could arise in the future.

Stakeholder Impact

• Shareholders: Will receive $28.25 per share in cash, providing immediate and certain value for their investment.
• Employees: Expected to have substantially comparable total cash compensation and benefits; Patient Square is committed to investing in them; however, equity-based programs will be adjusted. Day-to-day responsibilities remain unchanged until closing.
• Customers/Members/Partners: Business operations will continue as usual. Enhanced financial flexibility under new ownership is expected to accelerate product advancement and innovation, potentially benefiting these stakeholders in the long term.

Next Steps

• Premier stockholders must approve the proposed transaction.
• Required regulatory approvals must be obtained.
• Other customary closing conditions must be satisfied.
• Premier will file a definitive proxy statement on Schedule 14A with the SEC.
• Premier will continue to operate as a public company until the transaction closes.
• Employees are expected to maintain focus on their day-to-day priorities and responsibilities.
• Adjustments to equity-based compensation programs are anticipated following the closing of the transaction.

Key Dates

Recommendation

The definitive agreement for Premier, Inc. to be acquired by Patient Square Capital at $28.25 per share in cash provides immediate and certain value to stockholders. This represents a clear premium and a favorable exit for existing shareholders. For investors, any current trading price below $28.25 presents a low-risk arbitrage opportunity, assuming the transaction successfully closes by Q1 2026, subject to regulatory and shareholder approvals. The Board's unanimous approval further supports the deal's viability.

Keywords

Healthcare, Acquisition, Merger, Private Equity, Patient Square Capital, Premier Inc, SEC Filing, DEFA14A, Stock Buyout, Healthcare Technology, Supply Chain, Advisory Services